BioMarin Releases Results of Phase 1/2 Study of Gene Therapy Treatment
Note: The below is an edited version of a press release issued by BioMarin Pharmaceutical Inc. The original release can be read in its entirety here.
BioMarin Pharmaceutical announced today positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. Nine patients with severe hemophilia A received a single dose of BMN 270. Six of the seven patients treated with the highest dose had Factor VIII levels above 50% as of each patient’s most recent reading (between 12 and 28 weeks post-treatment). Two patients with Factor VIII levels above 200% had no unexpected events or need for medical intervention. No clinically relevant sustained rises in ALT levels or other markers of liver toxicity were observed.
Assisting and Advocating for the Bleeding Disorders Community